FDA Acting Rx-to-OTC Switch Review Leader Prioritizes Personnel
This article was originally published in The Tan Sheet
Shaw Chen, acting director of FDA’s Division of Nonprescription Clinical Evaluation, wants to stabilize the division’s staffing during a period of management transition. On the same CHPA conference panel, OTC monograph division chief Scott Furness shares some good news on time and extent applications.
You may also be interested in...
The Public Access to SunScreens Coalition will recommend a user fee program to improve FDA’s work on TEAs for OTC ingredients. “Despite a number of OTC applications waiting for approval for several years, FDA has not completed the review of applications for any new sunscreen components,” PASS says.
CDER recommends the OTC industry ensure product innovations comply with monographs or have FDA approval prior to marketing. Umbrella-branding and facility registration rank high for the drug center in 2013.
NaZura BioHealth, spun out from Elcelyx Therapeutics, will market its Lovidia weight-loss product in 2014 when it launches into the direct-response channel, before potential suitors get serious about acquiring the brand.